Abstract
Skin cancer is the most common malignancy in humans with basal cell carcinoma representing the majority of cases in the general population. The prevalence of skin cancer is increased amongst immunosuppressed patients such as those with lymphoproliferative disorders including non-Hodgkin lymphoma and chronic lymphocytic leukemia or those with iatrogenic immunosuppression following organ transplantation. In addition, these patients experience greater morbidity and mortality associated with skin cancers. The most common skin cancer in immunosuppressed patients is squamous cell carcinoma, which often presents with more aggressive features and has a greater rate of metastasis. This article reviews the risk factors, etiology, clinical presentation, and prevalence of skin cancer amongst immunosuppressed patients, including organ transplant, lymphoproliferative disorders, autoimmune disorders, and human immunodeficiency virus. We also provide a comprehensive review of treatment guidelines for immunosuppressed patients with cutaneous malignancy. Surgical therapy is the cornerstone of treatment; however, we also discuss pharmacologic treatment options, lifestyle modifications, and revision of immunosuppressive regimens.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 339-356 |
| Number of pages | 18 |
| Journal | American Journal of Clinical Dermatology |
| Volume | 15 |
| Issue number | 4 |
| DOIs | |
| State | Published - 2014 |
Fingerprint
ASJC Scopus subject areas
- Dermatology
- Medicine(all)
Cite this
Optimal management of skin cancer in immunosuppressed patients. / Brin, Lauren; Zubair, Adeel S.; Brewer, Jerry D.
In: American Journal of Clinical Dermatology, Vol. 15, No. 4, 2014, p. 339-356.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Optimal management of skin cancer in immunosuppressed patients
AU - Brin, Lauren
AU - Zubair, Adeel S.
AU - Brewer, Jerry D.
PY - 2014
Y1 - 2014
N2 - Skin cancer is the most common malignancy in humans with basal cell carcinoma representing the majority of cases in the general population. The prevalence of skin cancer is increased amongst immunosuppressed patients such as those with lymphoproliferative disorders including non-Hodgkin lymphoma and chronic lymphocytic leukemia or those with iatrogenic immunosuppression following organ transplantation. In addition, these patients experience greater morbidity and mortality associated with skin cancers. The most common skin cancer in immunosuppressed patients is squamous cell carcinoma, which often presents with more aggressive features and has a greater rate of metastasis. This article reviews the risk factors, etiology, clinical presentation, and prevalence of skin cancer amongst immunosuppressed patients, including organ transplant, lymphoproliferative disorders, autoimmune disorders, and human immunodeficiency virus. We also provide a comprehensive review of treatment guidelines for immunosuppressed patients with cutaneous malignancy. Surgical therapy is the cornerstone of treatment; however, we also discuss pharmacologic treatment options, lifestyle modifications, and revision of immunosuppressive regimens.
AB - Skin cancer is the most common malignancy in humans with basal cell carcinoma representing the majority of cases in the general population. The prevalence of skin cancer is increased amongst immunosuppressed patients such as those with lymphoproliferative disorders including non-Hodgkin lymphoma and chronic lymphocytic leukemia or those with iatrogenic immunosuppression following organ transplantation. In addition, these patients experience greater morbidity and mortality associated with skin cancers. The most common skin cancer in immunosuppressed patients is squamous cell carcinoma, which often presents with more aggressive features and has a greater rate of metastasis. This article reviews the risk factors, etiology, clinical presentation, and prevalence of skin cancer amongst immunosuppressed patients, including organ transplant, lymphoproliferative disorders, autoimmune disorders, and human immunodeficiency virus. We also provide a comprehensive review of treatment guidelines for immunosuppressed patients with cutaneous malignancy. Surgical therapy is the cornerstone of treatment; however, we also discuss pharmacologic treatment options, lifestyle modifications, and revision of immunosuppressive regimens.
UR - http://www.scopus.com/inward/record.url?scp=84904509354&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84904509354&partnerID=8YFLogxK
U2 - 10.1007/s40257-014-0085-5
DO - 10.1007/s40257-014-0085-5
M3 - Article
C2 - 25015705
AN - SCOPUS:84904509354
VL - 15
SP - 339
EP - 356
JO - American Journal of Clinical Dermatology
JF - American Journal of Clinical Dermatology
SN - 1175-0561
IS - 4
ER -